Fractyl Laboratories
Dirigeants
Voir l'organigramme avec ses 16 principaux dirigeants
Biographies les plus recherchées chez Fractyl Laboratories
- Harith Rajagopalan, Chief Executive Officer and Director
- Allan Will, Chairman of the Board
- Kelly Barnes, Director
Changements de dirigeants chez Fractyl Laboratories
- Timothy Kieffer, a rejoint l'entreprise comme Chief Scientific Officer (publié le 17 septembre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Fractyl Laboratories.
Biotechnologie
Fractyl Laboratories a 2 292 concurrents dont Lonza (Suisse), Eurofins (Luxembourg) et Deepull (Espagne).
Actualités en fusion/acquisition en Biotechnologie.
- Rapport Therapeutics vient d'annoncer une levée de fonds de 154 millions de dollars. (publié le 11 juin 2024).
- Amber Therapeutics vient d'annoncer une levée de fonds de 100 millions de dollars. (publié le 10 juin 2024).
- Restor3d vient d'annoncer une levée de fonds de 70 millions de dollars. (publié le 8 juin 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Fractyl Laboratories
- Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting | Fractyl Health, Inc.
- Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Fractyl Health, Inc.
- Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs | Fractyl Health, Inc.
- Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes | Fractyl Health, Inc.
- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity | Fractyl
- Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials | Fractyl Health, Inc.
- Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in it's Rejuva® GLP-1 Gene Therapy Platform | Fractyl Health, Inc.
- Events & Presentations | Fractyl Health, Inc.
- Fractyl Health Announces Pricing of Initial Public Offering | Fractyl Health, Inc.
- In the News | Fractyl Health, Inc.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Fractyl Laboratories
- Fractyl Laboratories sur Wikipédia, Google News & Yahoo Finance en 1-click
- Fractyl Laboratories sur LinkedIn, Twitter & YouTube en 1-click
